Georgel P. Taranu

Georgel P. Taranu

Auto-generated profile, based on publicly available information

Georgel P. Taranu

Clinical Emergency County Hospital Timisoara, Timis, Romania

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Current Neurovascular Research
Verified
Journal Article
Closed access
PDF file
AAAndrei Anghel
Andrei Anghel
GTGeorgel Taranu
Georgel Taranu
ESEdward Seclaman
Edward Seclaman
ARAndreea Luciana Rata
Andreea Luciana Rata
LTLiviu Athos Tamas
Liviu Athos Tamas
Aurel Popa-WagnerAurel Popa-Wagner
Aurel Popa-Wagner
The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.

12 October 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
GTGeorgel P. Taranu
Georgel P. Taranu
Mihai IonacMihai Ionac
Mihai Ionac